Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the growth stocks that could double by 2027. On July 14, CORT ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the 13 Best Low Risk High Growth Stocks to Buy. Analysts are ...

Corcept Therapeutics CORT announced that it has submitted a new drug application (NDA) to the FDA seeking approval for its ...

Detailed price information for Corcept Therapeutics (CORT-Q) from The Globe and Mail including charting and trades.

Corcept is developing relacorilant in ovarian cancer and a variety of other serious disorders, including endogenous hypercortisolism and prostate cancer.

Corcept Therapeutics has filed for U.S. Food and Drug Administration approval of its relacorilant drug candidate for the treatment of patients with platinum-resistant ovarian cancer. Corcept on ...

Corcept Submits NDA For Relacorilant To Treat Platinum-Resistant Ovarian Cancer July 14, 2025 — 01:03 pm EDT Written by RTTNews.com for RTTNews -> ...

Detailed price information for Corcept Therapeutics (CORT-Q) from The Globe and Mail including charting and trades.

US ovarian cancer mortality declined from 1999 to 2020, but significant disparities remain among older women, non-Hispanic White women, and those living in rural areas, as well as in the Northeastern ...

In a recent paper published in Nature, researchers at the University of Chicago discovered how to block nicotinamide N-methyl ...